Table 3.
Antiviral activity of representative SBA compounds against drug-resistant HBV mutants
| Compound | EC50 (μM) against the indicated HBVa |
|||||
|---|---|---|---|---|---|---|
| wt | rtL180 M/rtM204V | rtA181V | rtN236T | rtM204I | rtL180 M/rtM204V/rtT184G/rtS202I | |
| Lamivudine | 0.354 (±0.006) | >10 | 0.090 (±0.001) | 0.346 (±0.015) | >10 | >10 |
| Entecavir | 0.022 (±0.002) | 0.778 (±0.405) | 0.041 (±0.000) | 0.018 (±0.003) | 2.027 (±0.035) | >10 |
| Adefovir | 0.349 (±0.002) | 0.862 (±0.064) | 0.360 (±0.004) | 0.710 (±0.005) | 0.440 (±0.002) | 1.520 (±0.036) |
| DVR-01 | 2.899 (±0.140) | 3.273 (±0.107) | 3.180 (±0.347) | 2.752 (±0.173) | 2.567 (±0.057) | 2.403 (±0.569) |
| DVR-23 | 0.779 (±0.008) | 0.568 (±0.025) | 0.159 (±0.031) | 0.858 (±0.121) | 0.149 (±0.010) | 1.753 (±0.303) |
a
Mean values (± standard derivations) are presented from duplicate experiments.